免费获得国外相关药品，最快 1 个工作日回馈药物信息
出境医 / 临床实验 / The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
Study Description
Brief Summary:
Estimated glomerular filtration rate(eGFR) is significantly reduced in patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study is to research that the incidence of adverse cardiovascular events (MACE) in patients with ST-segment elevation myocardial infarction is significantly higher when the glomerular filtration rate below a certain value.
| Condition or disease |
|---|
| ST Elevation Myocardial Infarction |
Detailed Description:
The investigators retrospectively analyzed the clinical data of 1157 patients with ST-segment elevation myocardial infarction. In-hospital adverse cardiovascular events (MACE) was defined as: cardiac arrest, cardiac rupture, malignant arrhythmia, and cardiac death. All the patients were divided into 3 groups according to the patient's estimated glomerular filtration rate(eGFR) (eGFR≥90ml/min/1.73m2; 90ml/min/1.73m2>eGFR≥60ml/min/1.73m2; eGFR<60ml/min /1.73m2). COX regression analysis and K-M survival curves are used to calculate the correlation between eGFR and in-hospital MACE.
Study Design
| Study Type : | Observational |
| Actual Enrollment : | 3 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | The Predictive Value of Estimated Glomerular Filtration Rate (eGFR) for Adverse Cardiovascular Events in the Hospital in Patients With ST-segment Elevation |
| Actual Study Start Date : | October 1, 2015 |
| Actual Primary Completion Date : | February 28, 2018 |
| Actual Study Completion Date : | February 28, 2018 |
Arms and Interventions
Outcome Measures
Primary Outcome Measures :
- major adverse cardiac events [ Time Frame: The median time of 7 days ]Relationship between reduced eGFR and in-hospital MACE
Eligibility Criteria
| Ages Eligible for Study: | 24 Years to 93 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Study Population
STEMI Patients
Criteria
Inclusion Criteria:
- 1.Patients with STEMI 2.Patients from whom informed consent has been properly obtained in writing prior to start of the trial
Exclusion Criteria:
- 1.Patients with previous myocardial infarction, congenital heart disease 2.Patients with liver disease, and renal failure 3.Patients with immunologic disease, malignant tumors, pregnancy, infection caused by various pathogens, chronic inflammatory disease, trauma.
Contacts and Locations
No Contacts or Locations Provided
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Submitted Date | June 11, 2019 | ||||
| First Posted Date | June 12, 2019 | ||||
| Last Update Posted Date | June 12, 2019 | ||||
| Actual Study Start Date | October 1, 2015 | ||||
| Actual Primary Completion Date | February 28, 2018 (Final data collection date for primary outcome measure) | ||||
| Current Primary Outcome Measures |
major adverse cardiac events [ Time Frame: The median time of 7 days ] Relationship between reduced eGFR and in-hospital MACE
|
||||
| Original Primary Outcome Measures | Same as current | ||||
| Change History | No Changes Posted | ||||
| Current Secondary Outcome Measures | Not Provided | ||||
| Original Secondary Outcome Measures | Not Provided | ||||
| Current Other Pre-specified Outcome Measures | Not Provided | ||||
| Original Other Pre-specified Outcome Measures | Not Provided | ||||
| Descriptive Information | |||||
| Brief Title | The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI | ||||
| Official Title | The Predictive Value of Estimated Glomerular Filtration Rate (eGFR) for Adverse Cardiovascular Events in the Hospital in Patients With ST-segment Elevation | ||||
| Brief Summary | Estimated glomerular filtration rate(eGFR) is significantly reduced in patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study is to research that the incidence of adverse cardiovascular events (MACE) in patients with ST-segment elevation myocardial infarction is significantly higher when the glomerular filtration rate below a certain value. | ||||
| Detailed Description | The investigators retrospectively analyzed the clinical data of 1157 patients with ST-segment elevation myocardial infarction. In-hospital adverse cardiovascular events (MACE) was defined as: cardiac arrest, cardiac rupture, malignant arrhythmia, and cardiac death. All the patients were divided into 3 groups according to the patient's estimated glomerular filtration rate(eGFR) (eGFR≥90ml/min/1.73m2; 90ml/min/1.73m2>eGFR≥60ml/min/1.73m2; eGFR<60ml/min /1.73m2). COX regression analysis and K-M survival curves are used to calculate the correlation between eGFR and in-hospital MACE. | ||||
| Study Type | Observational | ||||
| Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Probability Sample | ||||
| Study Population | STEMI Patients | ||||
| Condition | ST Elevation Myocardial Infarction | ||||
| Intervention | Not Provided | ||||
| Study Groups/Cohorts | Not Provided | ||||
| Publications * | Not Provided | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status | Completed | ||||
| Actual Enrollment |
3 | ||||
| Original Actual Enrollment | Same as current | ||||
| Actual Study Completion Date | February 28, 2018 | ||||
| Actual Primary Completion Date | February 28, 2018 (Final data collection date for primary outcome measure) | ||||
| Eligibility Criteria |
Inclusion Criteria:
Exclusion Criteria:
|
||||
| Sex/Gender |
|
||||
| Ages | 24 Years to 93 Years (Adult, Older Adult) | ||||
| Accepts Healthy Volunteers | Yes | ||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
| Listed Location Countries | Not Provided | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT03984071 | ||||
| Other Study ID Numbers | 2019-06-11 | ||||
| Has Data Monitoring Committee | No | ||||
| U.S. FDA-regulated Product |
|
||||
| IPD Sharing Statement | Not Provided | ||||
| Responsible Party | Dongying Zhang, Chongqing Medical University | ||||
| Study Sponsor | Dongying Zhang | ||||
| Collaborators | Not Provided | ||||
| Investigators | Not Provided | ||||
| PRS Account | Chongqing Medical University | ||||
| Verification Date | June 2019 | ||||
